Basic Information
BOOSTRIX POLIO SUSPENSION FOR INJECTION
INJECTION, SUSPENSION
Regulatory Information
SIN15888P
February 20, 2020
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07CA02
Company Information
Active Ingredients
Strength: 5.0 Lf/0.5ml - not less than 20 IU
Strength: 2.5 Lf/ 0.5 ml - not less than 2 IU
Strength: 8 mcg/0.5ml
Strength: 2.5 mcg/0.5 ml
Strength: 8 mcg/0.5 ml
Strength: 40 DU/0.5 ml
Strength: 32 DU/0.5 ml
Strength: 8 DU/0.5 ml
Detailed Information
Contraindications
**Contraindications** Boostrix Polio should not be administered to subjects with known hypersensitivity to any component of the vaccine (see _Quantitative and Qualitative composition_ and _List of Excipients_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) or to subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis or poliomyelitis vaccines. Boostrix Polio is contraindicated if the subject has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine. In these circumstances, pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria, tetanus and poliomyelitis vaccines. Boostrix Polio should not be administered to subjects who have experienced neurological complications following an earlier immunisation against diphtheria and/or tetanus (for convulsions or hypotonic-hyporesponsive episodes, see _Warnings and Precautions_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**Indications** Boostrix Polio is indicated for booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of three years onwards (see _Posology_). The use of Boostrix Polio should be in accordance with official recommendations.